Article

Inhibition of p-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cells

2020-07-16

Abstract excerpt

The aim of this study is to determine whether manipulation of the drug transporter P-glycoprotein improves the efficacy of proteasome inhibitors in multiple myeloma cells. P-glycoprotein is a well-known drug transporter that is associated with chemotherapy resistance in a number of cancers but its role in modulating the efficacy of proteasome inhibitors in multiple myeloma is not well understood. Research has show...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 357ebf69-aca6-5f0e-b30a-ec6c5fa66b7b
DOI: 10.1101/2020.07.16.206102

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibition of p-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cellsDOI 10.1101/2020.07.16.206102Read

Overcoming rapaprotin resistance through inhibition of P-glycoproteinSemantic proximity Read

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunitsSemantic proximity Read

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myelomaSemantic proximity Read

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibSemantic proximity Read

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma ModelSemantic proximity Read

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myelomaSemantic proximity Read

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myelomaSemantic proximity Read

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.Semantic proximity Read

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaSemantic proximity Read